Prothena(PRTA)

Search documents
Prothena(PRTA) - 2024 Q4 - Annual Results
2025-02-20 21:07
Exhibit 99.1 PRESS RELEASE Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights DUBLIN, Ireland, February 20, 2025-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2024. In addition, the Company provided business highlights and 2025 fi ...
Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm
Newsfilter· 2025-02-17 23:10
Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Prothena Corporation PLC, focusing on possible self-dealing that may affect shareholders [1]. Group 1 - The investigation by Kuehn Law concerns whether certain officers and directors of Prothena Corporation PLC have engaged in self-dealing, which could lead to damages and corporate governance reforms for shareholders [1]. - Shareholders of Prothena Corporation PLC are encouraged to contact Kuehn Law for a free consultation regarding their rights and potential claims [2]. - The firm emphasizes the importance of shareholder participation in maintaining the integrity and fairness of financial markets [3].
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
ZACKS· 2024-12-12 17:36
A month has gone by since the last earnings report for Prothena (PRTA) . Shares have lost about 17.9% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Prothena due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Prothena Q3 Earnings Beat Estimates, Pipeline Progress in ...
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
ZACKS· 2024-11-13 13:51
Prothena Corporation (PRTA) reported a loss per share of $1.10 per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.18.In the year-ago quarter, the company posted earnings of 38 cents per share, driven by higher revenues.Third-quarter 2024 revenues totaled $1 million, which missed the Zacks Consensus Estimate of $2 million. PRTA recorded revenues of $85 million in the third quarter of 2023 on the back of collaboration revenues from partner Bristol Myers Squibb ( ...
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
ZACKS· 2024-11-13 00:00
Prothena (PRTA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.78%. A quarter ago, it was expected that this drug developer would post a loss of $1.01 per share when it actually produced earnings of $1.22, delivering a surprise of 220.79%.Over the last four quarters, the company has su ...
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
ZACKS· 2024-10-29 17:01
Prothena (PRTA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. In ...
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
ZACKS· 2024-10-29 09:50
Prothena (PRTA) shares rallied 15% in the last trading session to close at $17.59. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 23.7% loss over the past four weeks.Prothena owns a robust Alzheimer's Disease (“AD”) pipeline that spans next-generation antibody immunotherapy, small molecules and vaccines. The pipeline progress has been encouraging. PRTA's collaboration with bigwigs like Roche and Bristol Myer ...
What Makes Prothena (PRTA) a New Buy Stock
ZACKS· 2024-08-19 17:01
Prothena (PRTA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a changing e ...
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
ZACKS· 2024-08-09 14:21
Prothena Corporation (PRTA) reported earnings per share of $1.22 per share in the second quarter of 2024, and the Zacks Consensus Estimate for the same was pegged at a loss of $1.01 per share. In the year-ago quarter, the company posted a loss of $1.03 per share. The upside in earnings was driven by higher revenues. Revenues totaled $132 million, which beat the Zacks Consensus Estimate of $22 million and improved significantly from $4 million in the year-ago quarter. Collaboration fees recognized under an a ...
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
ZACKS· 2024-08-08 23:41
Prothena (PRTA) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of a loss of $1.01 per share. This compares to loss of $1.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 220.79%. A quarter ago, it was expected that this drug developer would post a loss of $1.21 per share when it actually produced a loss of $1.34, delivering a surprise of -10.74%. Over the last four quarters, the co ...